華東醫藥：HDM1002作為具有差異化的口服GLP-1靶向藥物，其定位正是為了滿足全球市場未滿足和差異化的臨牀需求

證券日報

01/27

登入新浪財經APP 搜索【信披】查看更多考評等級證券日報網訊 1月27日，華東醫藥在互動平台回答投資者提問時表示，HDM1002作為具有差異化的口服GLP-1靶向藥物，其定位正是為了滿足全球市場未滿足和差異化的臨牀需求。公司始終秉持開放合作戰略，在強化自主研發的同時，積極與全球同行一起探索創新藥管線的BD機會。未來如達成明確合作協議，公司將嚴格按照信息披露規則履行披露義務。（文章來源：證券日報）...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2606786830"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2606786830\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2606786830?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-01-27 18:38","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2606786830","market":"fut","top_or_hot":-1,"title":"華東醫藥：HDM1002作為具有差異化的口服GLP-1靶向藥物，其定位正是為了滿足全球市場未滿足和差異化的臨牀需求","media":"證券日報 ","content":"<div>\n<p>登入新浪財經APP 搜索【信披】查看更多考評等級\n證券日報網訊 1月27日，華東醫藥在互動平台回答投資者提問時表示，HDM1002作為具有差異化的口服GLP-1靶向藥物，其定位正是為了滿足全球市場未滿足和差異化的臨牀需求。公司始終秉持開放合作戰略，在強化自主研發的同時，積極與全球同行一起探索創新藥管線的BD機會。未來如達成明確合作協議，公司將嚴格按照信息披露規則履行披露義務。（文章來源：證券日報）...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/relnews/cn/2026-01-27/doc-inhitxiw5639046.shtml\">網頁鏈接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>華東醫藥：HDM1002作為具有差異化的口服GLP-1靶向藥物，其定位正是為了滿足全球市場未滿足和差異化的臨牀需求</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n華東醫藥：HDM1002作為具有差異化的口服GLP-1靶向藥物，其定位正是為了滿足全球市場未滿足和差異化的臨牀需求\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">證券日報 </strong><span class=\"h-time small\">2026-01-27 18:38</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>登入新浪財經APP 搜索【信披】查看更多考評等級\n證券日報網訊 1月27日，華東醫藥在互動平台回答投資者提問時表示，HDM1002作為具有差異化的口服GLP-1靶向藥物，其定位正是為了滿足全球市場未滿足和差異化的臨牀需求。公司始終秉持開放合作戰略，在強化自主研發的同時，積極與全球同行一起探索創新藥管線的BD機會。未來如達成明確合作協議，公司將嚴格按照信息披露規則履行披露義務。（文章來源：證券日報）...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/relnews/cn/2026-01-27/doc-inhitxiw5639046.shtml\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.sina.com.cn/stock/relnews/cn/2026-01-27/doc-inhitxiw5639046.shtml\">證券日報 </a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0196","symbol_name":"行業龍頭","start_time":0,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-27/doc-inhitxiw5639046.shtml","article_id":"2606786830","we_media_id":null,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-27/doc-inhitxiw5639046.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2606786830","pubTimestamp":1769510280,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"登入新浪財經APP 搜索【信披】查看更多考評等級\n證券日報網訊 1月27日，華東醫藥在互動平台回答投資者提問時表示，HDM1002作為具有差異化的口服GLP-1靶向藥物，其定位正是為了滿足全球市場未滿足和差異化的臨床需求。公司始終秉持開放合作戰略，在強化自主研發的同時，積極與全球同行一起探索創新藥管線的BD機會。未來如達成明確合作協議，公司將嚴格按照信息披露規則履行披露義務。（文章來源：證券日報）\n\n\n海量資訊、精準解讀，盡在新浪財經APP","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK0196":"行业龙头","BK0175":"白马股","BK0187":"一线龙头","000963":"华东医药","BK4144":"石油与天然气的储存和运输","BK0188":"融资融券","GLP":"Global Partners Lp","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK0132":"高送转概念","BK0209":"零售","BK0183":"MSCI概念","BK4590":"PTP","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD"},"translate_title":"Huadong Medicine: As a differentiated oral GLP-1 targeted drug, HDM1002 is positioned to meet the unmet and differentiated clinical needs of the global market","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLP":1.5,"000963":1.5},"content_text":"登入新浪財經APP 搜索【信披】查看更多考評等級\n證券日報網訊 1月27日，華東醫藥在互動平台回答投資者提問時表示，HDM1002作為具有差異化的口服GLP-1靶向藥物，其定位正是為了滿足全球市場未滿足和差異化的臨床需求。公司始終秉持開放合作戰略，在強化自主研發的同時，積極與全球同行一起探索創新藥管線的BD機會。未來如達成明確合作協議，公司將嚴格按照信息披露規則履行披露義務。（文章來源：證券日報）\n\n\n海量資訊、精準解讀，盡在新浪財經APP","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}